0001504776FALSE2023Q112/3100015047762023-01-012023-03-310001504776us-gaap:CommonClassAMember2023-05-05xbrli:shares0001504776us-gaap:CommonClassBMember2023-05-0500015047762023-03-31iso4217:USD00015047762022-12-31iso4217:USDxbrli:shares0001504776us-gaap:CommonClassAMember2022-12-310001504776us-gaap:CommonClassAMember2023-03-310001504776us-gaap:CommonClassBMember2022-12-310001504776us-gaap:CommonClassBMember2023-03-3100015047762022-01-012022-03-310001504776wrby:CommonClassAAndBMemberus-gaap:CommonStockMember2022-12-310001504776us-gaap:AdditionalPaidInCapitalMember2022-12-310001504776us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001504776us-gaap:RetainedEarningsMember2022-12-310001504776wrby:CommonClassAAndBMemberus-gaap:CommonStockMember2023-01-012023-03-310001504776us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001504776us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001504776us-gaap:RetainedEarningsMember2023-01-012023-03-310001504776wrby:CommonClassAAndBMemberus-gaap:CommonStockMember2023-03-310001504776us-gaap:AdditionalPaidInCapitalMember2023-03-310001504776us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001504776us-gaap:RetainedEarningsMember2023-03-310001504776wrby:CommonClassAAndBMemberus-gaap:CommonStockMember2021-12-310001504776us-gaap:AdditionalPaidInCapitalMember2021-12-310001504776us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001504776us-gaap:RetainedEarningsMember2021-12-3100015047762021-12-310001504776wrby:CommonClassAAndBMemberus-gaap:CommonStockMember2022-01-012022-03-310001504776us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001504776us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001504776us-gaap:RetainedEarningsMember2022-01-012022-03-310001504776wrby:CommonClassAAndBMemberus-gaap:CommonStockMember2022-03-310001504776us-gaap:AdditionalPaidInCapitalMember2022-03-310001504776us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001504776us-gaap:RetainedEarningsMember2022-03-3100015047762022-03-31wrby:segment0001504776us-gaap:CostOfGoodsTotalMemberwrby:TopFiveInventorySuppliersMemberus-gaap:SupplierConcentrationRiskMember2023-01-012023-03-31xbrli:pure0001504776us-gaap:CostOfGoodsTotalMemberwrby:TopFiveInventorySuppliersMemberus-gaap:SupplierConcentrationRiskMember2022-01-012022-03-310001504776us-gaap:CreditCardReceivablesMember2023-03-310001504776us-gaap:CreditCardReceivablesMember2022-12-310001504776us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-03-310001504776us-gaap:OtherNoncurrentAssetsMember2023-03-310001504776wrby:EyewearProductsMember2023-01-012023-03-310001504776wrby:EyewearProductsMember2022-01-012022-03-310001504776wrby:ServicesAndOtherMember2023-01-012023-03-310001504776wrby:ServicesAndOtherMember2022-01-012022-03-310001504776wrby:ECommerceMember2023-01-012023-03-310001504776wrby:ECommerceMember2022-01-012022-03-310001504776us-gaap:RetailMember2023-01-012023-03-310001504776us-gaap:RetailMember2022-01-012022-03-310001504776us-gaap:LeaseholdImprovementsMember2023-03-310001504776us-gaap:LeaseholdImprovementsMember2022-12-310001504776us-gaap:ComputerEquipmentMember2023-03-310001504776us-gaap:ComputerEquipmentMember2022-12-310001504776us-gaap:FurnitureAndFixturesMember2023-03-310001504776us-gaap:FurnitureAndFixturesMember2022-12-310001504776us-gaap:SoftwareDevelopmentMember2023-03-310001504776us-gaap:SoftwareDevelopmentMember2022-12-310001504776us-gaap:ConstructionInProgressMember2023-03-310001504776us-gaap:ConstructionInProgressMember2022-12-310001504776us-gaap:CostOfSalesMember2023-01-012023-03-310001504776us-gaap:CostOfSalesMember2022-01-012022-03-310001504776us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001504776us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001504776wrby:TotalDepreciationDepletionAndAmortizationMember2023-01-012023-03-310001504776wrby:TotalDepreciationDepletionAndAmortizationMember2022-01-012022-03-310001504776us-gaap:CommonClassCMember2023-03-31wrby:vote0001504776us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassAMember2023-03-310001504776us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassBMember2023-03-310001504776us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassCMember2023-03-310001504776us-gaap:CommonClassAMemberwrby:PerformanceStockUnitsMember2023-03-310001504776wrby:PerformanceStockUnitsMemberus-gaap:CommonClassBMember2023-03-310001504776wrby:PerformanceStockUnitsMemberus-gaap:CommonClassCMember2023-03-310001504776us-gaap:CommonClassAMemberus-gaap:EmployeeStockMember2023-03-310001504776us-gaap:EmployeeStockMemberus-gaap:CommonClassBMember2023-03-310001504776us-gaap:EmployeeStockMemberus-gaap:CommonClassCMember2023-03-310001504776us-gaap:CommonClassAMemberwrby:A2021PlanMember2021-08-310001504776wrby:A2021PlanMember2021-08-012021-08-310001504776wrby:A2021IncentiveAwardPlanMemberwrby:StockOptionsOrRestrictedStockUnitsRSUsMember2021-08-012021-08-310001504776wrby:A2021PlanMember2022-01-012022-01-310001504776us-gaap:CommonClassAMemberwrby:ThePlansMember2022-12-310001504776wrby:A2021PlanMember2023-01-012023-01-310001504776us-gaap:CommonClassAMemberwrby:ThePlansMember2023-03-310001504776us-gaap:EmployeeStockMember2021-08-310001504776us-gaap:EmployeeStockMember2021-08-012021-08-310001504776us-gaap:EmployeeStockMember2022-01-012022-01-310001504776us-gaap:EmployeeStockMember2023-01-012023-01-310001504776us-gaap:EmployeeStockMember2023-03-310001504776us-gaap:EmployeeStockMember2023-01-012023-03-310001504776us-gaap:EmployeeStockMember2022-01-012022-03-310001504776wrby:FoundersGrantMember2023-01-012023-03-310001504776us-gaap:RestrictedStockUnitsRSUMemberwrby:A2021PlanMember2023-01-012023-03-310001504776wrby:FoundersGrantMember2022-01-012022-03-310001504776us-gaap:IPOMember2022-01-012022-03-3100015047762022-01-012022-09-300001504776us-gaap:EmployeeStockOptionMemberwrby:ThePlansMember2023-03-310001504776us-gaap:EmployeeStockOptionMemberwrby:ThePlansMember2023-01-012023-03-310001504776us-gaap:RestrictedStockUnitsRSUMember2022-12-310001504776us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001504776us-gaap:RestrictedStockUnitsRSUMember2023-03-310001504776us-gaap:RestrictedStockUnitsRSUMemberwrby:ThePlansMember2023-03-310001504776wrby:ThePlansMemberus-gaap:PerformanceSharesMember2023-03-310001504776us-gaap:RestrictedStockUnitsRSUMemberwrby:ThePlansMember2023-01-012023-03-310001504776wrby:ThePlansMemberus-gaap:PerformanceSharesMember2023-01-012023-03-310001504776wrby:FoundersGrantMemberus-gaap:PerformanceSharesMember2021-06-012021-06-300001504776us-gaap:RestrictedStockUnitsRSUMemberwrby:FoundersGrantMember2021-06-012021-06-300001504776us-gaap:PerformanceSharesMember2021-06-012021-06-30wrby:performanceCondition0001504776us-gaap:PerformanceSharesMemberus-gaap:CommonClassBMember2021-06-012021-06-300001504776us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:PerformanceSharesMember2023-03-310001504776us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:PerformanceSharesMember2023-03-310001504776us-gaap:ShareBasedCompensationAwardTrancheThreeMemberus-gaap:PerformanceSharesMember2023-03-310001504776wrby:ShareBasedPaymentArrangementTrancheFourMemberus-gaap:PerformanceSharesMember2023-03-310001504776wrby:ShareBasedPaymentArrangementTrancheFiveMemberus-gaap:PerformanceSharesMember2023-03-310001504776wrby:ShareBasedPaymentArrangementTrancheSixMemberus-gaap:PerformanceSharesMember2023-03-310001504776wrby:ShareBasedPaymentArrangementTrancheSevenMemberus-gaap:PerformanceSharesMember2023-03-310001504776wrby:ShareBasedPaymentArrangementTrancheEightMemberus-gaap:PerformanceSharesMember2023-03-310001504776wrby:MonteCarloSimulationMemberus-gaap:PerformanceSharesMember2023-01-012023-03-310001504776us-gaap:RestrictedStockUnitsRSUMemberwrby:FoundersGrantMember2023-01-012023-03-310001504776srt:MinimumMember2023-03-310001504776srt:MaximumMember2023-03-310001504776wrby:ComericaBankMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2013-08-310001504776wrby:CreditFacilityMemberwrby:ComericaBankMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2013-08-310001504776wrby:CreditFacilityMemberwrby:ComericaBankMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2013-08-012013-08-310001504776wrby:CreditFacilityMemberwrby:ComericaBankMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2013-08-310001504776wrby:ComericaBankMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-09-300001504776wrby:ComericaBankMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-09-300001504776wrby:ComericaBankMemberwrby:SwingLineNotesMemberus-gaap:LineOfCreditMember2022-09-300001504776wrby:ComericaBankMemberwrby:DebtInstrumentOptionToIncreaseMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-09-012022-09-300001504776wrby:ComericaBankMemberwrby:DebtInstrumentOptionToIncreaseMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-09-300001504776wrby:ComericaBankMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberwrby:FederalFundsRateMember2022-09-012022-09-300001504776wrby:ComericaBankMemberwrby:BloombergShortTermBankYieldIndexRateMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-09-012022-09-300001504776wrby:ComericaBankMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberwrby:FederalFundsRateMember2022-09-012022-09-300001504776wrby:ComericaBankMemberus-gaap:LineOfCreditMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberwrby:FederalFundsRateMember2022-09-012022-09-300001504776wrby:ComericaBankMembersrt:MinimumMemberwrby:BloombergShortTermBankYieldIndexRateMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-09-012022-09-300001504776wrby:ComericaBankMemberwrby:BloombergShortTermBankYieldIndexRateMemberus-gaap:LineOfCreditMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2022-09-012022-09-300001504776wrby:ComericaBankMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-09-012022-09-300001504776wrby:CreditFacilityMemberwrby:ComericaBankMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2023-03-310001504776wrby:CreditFacilityMemberwrby:ComericaBankMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-12-310001504776us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001504776us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001504776us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001504776us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001504776us-gaap:PerformanceSharesMember2023-01-012023-03-310001504776us-gaap:PerformanceSharesMember2022-01-012022-03-310001504776us-gaap:EmployeeStockMember2023-01-012023-03-310001504776us-gaap:EmployeeStockMember2022-01-012022-03-310001504776wrby:SecuredPromissoryNotesMembersrt:ManagementMember2023-01-012023-03-310001504776us-gaap:RelatedPartyMembersrt:ManagementMember2022-12-310001504776us-gaap:RelatedPartyMembersrt:ManagementMember2023-03-310001504776us-gaap:SubsequentEventMemberwrby:NewAndExtendedLeaseTermsRetailSpaceUnitedStatesMember2023-05-09wrby:leaseAgreement0001504776us-gaap:SubsequentEventMembersrt:MinimumMemberwrby:NewAndExtendedLeaseTermsRetailSpaceUnitedStatesMember2023-05-090001504776us-gaap:SubsequentEventMemberwrby:NewAndExtendedLeaseTermsRetailSpaceUnitedStatesMembersrt:MaximumMember2023-05-090001504776us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMemberus-gaap:CommonClassAMemberwrby:A2021PlanMember2023-04-012023-04-30
Item 1. Financial Statements
Warby Parker Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Unaudited)
(Amounts in thousands, except share data) | | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 |
Assets | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 204,261 | | | $ | 208,585 | |
Accounts receivable, net | 962 | | | 1,435 | |
Inventory | 64,411 | | | 68,848 | |
Prepaid expenses and other current assets | 14,927 | | | 15,700 | |
Total current assets | 284,561 | | | 294,568 | |
| | | |
Property and equipment, net | 140,476 | | | 138,628 | |
Right-of-use lease assets | 123,278 | | | 127,014 | |
Other assets | 9,566 | | | 8,497 | |
Total assets | $ | 557,881 | | | $ | 568,707 | |
| | | |
Liabilities and Stockholders’ Equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 19,958 | | | $ | 20,791 | |
Accrued expenses | 47,996 | | | 58,222 | |
Deferred revenue | 18,886 | | | 25,628 | |
Current lease liabilities | 21,710 | | | 22,546 | |
Other current liabilities | 2,489 | | | 2,370 | |
Total current liabilities | 111,039 | | | 129,557 | |
| | | |
Non-current lease liabilities | 148,922 | | | 150,832 | |
Other liabilities | 1,574 | | | 1,672 | |
Total liabilities | 261,535 | | | 282,061 | |
Commitments and contingencies (see Note 9) | | | |
Stockholders’ equity: | | | |
Common stock, $0.0001 par value; Class A: 750,000,000 shares authorized at March 31, 2023 and December 31, 2022, 96,282,522 and 96,115,202 issued and outstanding at March 31, 2023 and December 31, 2022, respectively; Class B: 150,000,000 shares authorized at March 31, 2023 and December 31, 2022, 19,318,298 and 19,223,572 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively, convertible to Class A on a one-to-one basis | 12 | | | 12 | |
Additional paid-in capital | 912,110 | | | 890,915 | |
Accumulated deficit | (614,446) | | | (603,634) | |
Accumulated other comprehensive loss | (1,330) | | | (647) | |
Total stockholders’ equity | 296,346 | | | 286,646 | |
Total liabilities and stockholders’ equity | $ | 557,881 | | | $ | 568,707 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Warby Parker Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(Amounts in thousands, except share and per share data) | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Net revenue | $ | 171,968 | | | $ | 153,218 | |
Cost of goods sold | 77,177 | | | 63,572 | |
Gross profit | 94,791 | | | 89,646 | |
| | | |
Selling, general, and administrative expenses | 107,221 | | | 123,386 | |
Loss from operations | (12,430) | | | (33,740) | |
| | | |
Interest and other loss, net | 1,879 | | | 146 | |
| | | |
Loss before income taxes | (10,551) | | | (33,594) | |
Provision for income taxes | 261 | | | 539 | |
Net loss | $ | (10,812) | | | $ | (34,133) | |
| | | |
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.09) | | | $ | (0.30) | |
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 116,159,428 | | | 114,103,766 | |
| | | |
Other comprehensive loss | | | |
Foreign currency translation adjustment | $ | (683) | | | $ | 8 | |
Total comprehensive loss | $ | (11,495) | | | $ | (34,125) | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Warby Parker Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)
(Amounts in thousands)
Three Months Ended March 31, 2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Class A and Class B Common Stock | | Additional Paid-In Capital | | Accumulated Other Comprehensive Income (Loss) | | Accumulated Deficit | | Total Stockholders’ Equity |
| Shares | | Amount | |
Balance as of December 31, 2022 | 115,339 | | | $ | 12 | | | $ | 890,915 | | | $ | (647) | | | $ | (603,634) | | | $ | 286,646 | |
Stock option exercises | 109 | | | — | | | 1,415 | | | — | | | — | | | 1,415 | |
Restricted stock unit releases | 153 | | | — | | | — | | | — | | | — | | | — | |
Stock-based compensation | — | | | — | | | 19,780 | | | — | | | — | | | 19,780 | |
Other comprehensive loss | — | | | — | | | — | | | (683) | | | — | | | (683) | |
Net loss | — | | | — | | | — | | | — | | | (10,812) | | | (10,812) | |
Balance as of March 31, 2023 | 115,601 | | | $ | 12 | | | $ | 912,110 | | | $ | (1,330) | | | $ | (614,446) | | | $ | 296,346 | |
Three Months Ended March 31, 2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Class A and Class B Common Stock | | Additional Paid-In Capital | | Accumulated Other Comprehensive Income (Loss) | | Accumulated Deficit | | Total Stockholders’ Equity |
| Shares | | Amount | |
Balance as of December 31, 2021 | 113,621 | | | 11 | | | $ | 779,212 | | | $ | 16 | | | $ | (493,241) | | | $ | 285,998 | |
Stock option exercises | 201 | | | — | | | 1,866 | | | — | | | — | | | 1,866 | |
Restricted stock unit releases | 147 | | | — | | | — | | | — | | | — | | | — | |
Stock-based compensation | — | | | — | | | 27,144 | | | — | | | — | | | 27,144 | |
Other comprehensive income | — | | | — | | | — | | | 8 | | | — | | | 8 | |
Net loss | — | | | — | | | — | | | — | | | (34,133) | | | (34,133) | |
Balance as of March 31, 2022 | 113,969 | | | $ | 11 | | | $ | 808,222 | | | $ | 24 | | | $ | (527,374) | | | $ | 280,883 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Warby Parker Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Amounts in thousands) | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Cash flows from operating activities | | | |
Net loss | $ | (10,812) | | | $ | (34,133) | |
Adjustments to reconcile net loss to net cash provided by operating activities: | | | |
Depreciation and amortization | 9,140 | | | 6,910 | |
Stock-based compensation | 19,780 | | | 27,144 | |
| | | |
Asset impairment charges | 395 | | | 227 | |
Amortization of cloud-based software implementation costs | 363 | | | — | |
Change in operating assets and liabilities: | | | |
Accounts receivable, net | 473 | | | 163 | |
Inventory | 4,442 | | | (7,147) | |
Prepaid expenses and other assets | (657) | | | (4,316) | |
Accounts payable | (921) | | | 751 | |
Accrued expenses | (7,826) | | | (2,158) | |
Deferred revenue | (6,744) | | | (2,654) | |
Other current liabilities | 119 | | | 129 | |
Right-of-use lease assets and current and non-current lease liabilities | 988 | | | 2,571 | |
Other liabilities | (97) | | | 2,217 | |
Net cash provided by (used in) operating activities | 8,643 | | | (10,296) | |
Cash flows from investing activities | | | |
Purchases of property and equipment | (12,385) | | | (16,060) | |
Net cash used in investing activities | (12,385) | | | (16,060) | |
Cash flows from financing activities | | | |
Proceeds from stock option exercises | 81 | | | 180 | |
| | | |
| | | |
| | | |
| | | |
Net cash provided by financing activities | 81 | | | 180 | |
Effect of exchange rates on cash | (662) | | | 84 | |
Net decrease in cash and cash equivalents | (4,323) | | | (26,092) | |
Cash and cash equivalents, beginning of period | 208,585 | | | 256,416 | |
Cash and cash equivalents, end of period | $ | 204,262 | | | $ | 230,324 | |
Supplemental disclosures | | | |
Cash paid for income taxes | $ | 97 | | | $ | 34 | |
Cash paid for interest | 50 | | | 35 | |
Cash paid for amounts included in the measurement of lease liabilities | 10,849 | | | 6,941 | |
Non-cash investing and financing activities: | | | |
Purchases of property and equipment included in accounts payable and accrued expenses | $ | 2,957 | | | $ | 4,241 | |
| | | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
1. Description of Business
Warby Parker Inc., a public benefit corporation founded in 2010 (together with its wholly owned subsidiaries, the “Company”), is a founder-led, mission-driven lifestyle brand that sits at the intersection of technology, design, healthcare, and social enterprise. The Company offers holistic vision care by selling eyewear products and providing optical services directly to consumers through its retail stores and e-commerce platform. For every pair of glasses or sunglasses sold, the Company helps distribute a pair of glasses to someone in need through its Buy a Pair, Give a Pair program. The Company is headquartered in New York, New York.
2. Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared and are presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). Certain information and disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2022 and the related notes. The December 31, 2022 condensed consolidated balance sheet was derived from the Company’s audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair presentation of the condensed consolidated financial statements. There have been no significant changes in accounting policies during the three months ended March 31, 2023 from those disclosed in the audited consolidated financial statements for the year ended December 31, 2022 and the related notes, except for the adoption of new accounting pronouncements as noted under the heading Recently Adopted Accounting Pronouncements below. Certain prior period amounts were reclassified to conform to the current period presentation. These changes had no impact on the condensed consolidated financial statements for any period.
Principles of Consolidation
The condensed consolidated financial statements include the financial statements of Warby Parker Inc., and its wholly owned subsidiaries. The Company has consolidated certain entities meeting the definition of a variable interest entity as the Company concluded that it is the primary beneficiary of the entities. The inclusion of these entities does not have a material impact on its condensed consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The Company prepares its condensed consolidated financial statements in conformity with U.S. GAAP. These principles require management to make certain estimates and assumptions during the preparation of its condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Management’s estimates are based on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Significant estimates underlying the accompanying condensed consolidated financial statements include, but are not limited to (i) the valuation of inventory, including the determination of the net realizable value, (ii) the useful lives and recoverability of long-lived assets, (iii) the determination of deferred income taxes, including related valuation allowances, and (iv) assumptions related to the valuation of common stock and determination of stock-based compensation.
Segment Information
Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker (“CODM”), who makes decisions about allocating resources and assessing performance. The Company defines its CODM as its co-Chief Executive Officers. The Company has identified one operating segment. When evaluating the Company’s performance and allocating resources, the CODM relies on financial information prepared on a consolidated basis.
Concentration of Credit Risk and Major Suppliers
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains its cash and cash equivalents in various accounts, which, at times, may exceed the limits insured by the Federal Deposit Insurance Corporation of $250 thousand per institution
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
and the Canada Deposit Insurance Corporation of $100 thousand Canadian dollars. At March 31, 2023 and December 31, 2022, uninsured cash balances were approximately $202.8 million and $207.0 million, respectively. The Company has not experienced any concentration losses related to its cash and cash equivalents to date. The Company seeks to minimize its credit risk by maintaining its cash and cash equivalents with high-quality financial institutions and monitoring the credit standing of such institutions. During the first quarter of 2023, the Company opened accounts with additional financial institutions to diversify its cash holdings.
The Company’s top five inventory suppliers accounted for approximately 19% and 23% of cost of goods sold for the three months ended March 31, 2023 and 2022, respectively.
Cash and Cash Equivalents
The Company considers all highly liquid short-term investments with an original maturity of three months or less to be a cash equivalent. Cash and cash equivalents include deposits with banks and financial institutions, money market funds, and receivables from credit card issuers, which are typically converted into cash within two to four days of capture. As such, these receivables are recorded as a deposit in transit as a component of cash and cash equivalents on the condensed consolidated balance sheets. At March 31, 2023 and December 31, 2022, the balance of receivables from credit card issuers included within cash and cash equivalents was $3.7 million and $11.1 million, respectively.
Inventory
Inventory consists of approximately $15.4 million and $16.1 million of finished goods, including ready-to-wear sun frames, contact lenses, and eyeglass cases, as of March 31, 2023 and December 31, 2022, respectively, and approximately $49.0 million and $52.7 million of component parts, including optical frames and prescription optical lenses, as of March 31, 2023 and December 31, 2022, respectively. Inventory is stated at the lower of cost or net realizable value, with cost determined on a weighted average cost basis.
The Company continuously evaluates the composition of its inventory and makes adjustments when the cost of inventory is not expected to be fully recoverable. The estimated net realizable value of inventory is determined based on an analysis of historical sales trends, the impact of market trends and economic conditions, a forecast of future demand, and the estimated timing of product retirements. Adjustments for damaged inventory are recorded primarily based on actual damaged inventory. Adjustments for inventory shrink, representing the physical loss of inventory, include estimates based on historical experience, and are adjusted based upon physical inventory counts. However, unforeseen adverse future economic and market conditions could result in actual results differing materially from estimates.
Cloud-Based Software Implementation Costs
The Company has entered into cloud-based software hosting arrangements for which it incurs implementation costs. Certain costs incurred during the application development stage are capitalized and included within prepaid expenses and other current assets or other assets, depending on the long or short-term nature of such costs, in line with the Company's policy on the accounting for prepaid software hosting arrangements. Costs incurred during the preliminary project stage and post-implementation stage are expensed as incurred. Capitalized cloud-based software implementation costs are amortized, beginning on the date the related software or module is ready for its intended use, on a straight-line basis over the remaining term of the hosting arrangement as a component of selling, general, and administrative expenses, the same line item as the expense for the associated hosting arrangement.
As of March 31, 2023, the Company had $13.8 million of gross capitalized cloud-based software implementation costs and $0.6 million of related accumulated amortization, for a net balance of $13.2 million, made up of $3.9 million recorded within prepaid expenses and other current assets and $9.3 million recorded within other assets on the condensed consolidated balance sheet. During the three months ended March 31, 2023, the Company incurred $0.4 million of amortization of capitalized cloud-based software implementation costs.
Revenue Recognition
The Company primarily derives revenue from the sales of eyewear products, optical services, and accessories. The Company sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges, which are charged to the customer, associated with these purchases. Revenue generated from services consists of both in-person eye exams and prescriptions issued through the Virtual Vision Test app. All revenue is reported net of sales taxes collected from customers on behalf of taxing authorities and variable consideration, including returns and discounts.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
Revenue is recognized when performance obligations are satisfied through either the transfer of control of promised goods or the rendering of services to the Company's customers. Control transfers once a customer has the ability to direct the use of, and obtain substantially all of the benefits from, the product, which is generally determined to be the point of delivery or upon rendering of the service in the case of eye exams. This includes the transfer of legal title, physical possession, the risks and rewards of ownership, and customer acceptance. In the normal course of business, payment may be collected from the customer prior to recognizing revenue and such cash receipts are included in deferred revenue until the order is delivered to the customer. Substantially all of the deferred revenue included on the balance sheet at December 31, 2022 was recognized as revenue in the first quarter of 2023 and the Company expects substantially all of the deferred revenue at March 31, 2023 to be recognized as revenue in the second quarter of 2023.
The Company’s sales policy allows customers to return merchandise for any reason within 30 days of receipt, generally for an exchange or refund. An allowance is recorded within other current liabilities on the condensed consolidated balance sheets for expected future customer returns which the Company estimates using historical return patterns and its expectation of future returns. Any difference between the actual return and previous estimates is adjusted in the period in which such returns occur. Historical return estimates have not materially differed from actual returns in any of the periods presented. The allowance for returns was $2.3 million and $2.2 million at March 31, 2023 and December 31, 2022, respectively, and is included in other current liabilities on the condensed consolidated balance sheets.
The Company offers non-expiring gift cards to its customers. Proceeds from the sale of gift cards are initially deferred and recognized within deferred revenue on the condensed consolidated balance sheets, and are recognized as revenue when the product is received by the customer after the gift card has been tendered for payment. Based on historical experience, and to the extent there is no requirement to remit unclaimed card balances to government agencies under unclaimed property laws, an estimate of the gift card balances that will never be redeemed is recognized as revenue in proportion to gift cards which have been redeemed. While the Company will continue to honor all gift cards presented for payment, management may determine the likelihood of redemption to be remote for certain card balances due to, among other things, long periods of inactivity.
The following table disaggregates the Company’s revenue by product: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Eyewear products | $ | 162,347 | | | $ | 147,318 | |
Services and other | 9,621 | | | 5,900 | |
Total Revenue | $ | 171,968 | | | $ | 153,218 | |
The following table disaggregates the Company’s revenue by channel: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
E-commerce | $ | 61,751 | | | $ | 67,005 | |
Retail | 110,217 | | | 86,213 | |
Total Revenue | $ | 171,968 | | | $ | 153,218 | |
Leases
The Company records a lease liability and corresponding right-of-use (“ROU”) asset at lease commencement. The lease liability is measured at the present value of non-cancellable future lease payments over the lease term, minus expected tenant improvement allowances (“TIAs”) determined to be lease incentives. The ROU asset is measured at the lease liability amount, adjusted for prepaid lease payments, TIAs expected to be received, and any initial direct costs.
When calculating the present value of future lease payments, the Company utilizes an incremental borrowing rate, which incorporates several factors including the lease term, U.S. Treasury bond rates, financial ratios related to earnings and cash flows, and other comparisons with similarly sized companies.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
Many of the Company’s leases contain TIA provisions, which represent contractual amounts receivable from a lessor for improvements to the leased property made by the Company which are determined to represent lease incentives. The Company considers the collection of TIAs to be reasonably certain, and includes them in the present value calculation when determining the lease liabilities for new leases. The benefit from a TIA is amortized through rent expense over the term of the related lease.
The recognition of rent expense for an operating lease commences on the date at which control and possession of the property is obtained. Rent expense is calculated by recognizing total fixed minimum rental payments, net of any TIAs or other rental concessions, on a straight-line basis over the lease term. Some of the Company’s retail leases contain percent of sales rent or similar provisions, which is recognized as incurred as variable rent. Retail, optical laboratory, and distribution center rent expense is recognized as a component of cost of goods sold and all other rent expense is recognized as a component of selling, general, and administrative expenses.
Recent Accounting Pronouncements
The Company has not adopted nor are there any recently issued accounting pronouncements that had or are anticipated to have a material impact on the Company’s condensed consolidated financial statements.
3. Property and Equipment, Net
Property and equipment, net consists of the following: | | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 |
Leasehold improvements | $ | 142,658 | | | $ | 139,421 | |
Computers and equipment | 33,116 | | | 31,928 | |
Furniture and fixtures | 24,958 | | | 23,849 | |
Capitalized software | 19,611 | | | 18,876 | |
Construction in process | 15,072 | | | 12,924 | |
| 235,415 | | | 226,998 | |
Less: accumulated depreciation and amortization | (94,939) | | | (88,370) | |
Property and equipment, net | $ | 140,476 | | | $ | 138,628 | |
Expenses associated with property and equipment consisted of the following: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Cost of goods sold | $ | 6,029 | | | $ | 4,647 | |
Selling, general, and administrative expenses | 3,111 | | | 2,263 | |
Total depreciation and amortization expense | $ | 9,140 | | | $ | 6,910 | |
| | | |
Asset impairment charges | $ | 395 | | | $ | 227 | |
Asset impairment charges for the three months ended March 31, 2023 and 2022 primarily related to the write-off of assets in connection with retail store closures.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
4. Accrued Expenses
Accrued expenses consists of the following: | | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 |
Optical laboratory and product costs | $ | 8,786 | | | $ | 4,547 | |
Marketing | 7,187 | | | 8,353 | |
Unvested early exercised stock options | 6,452 | | | 7,784 | |
Payroll related | 6,437 | | | 11,149 | |
Charitable contributions | 5,294 | | | 6,001 | |
Professional services | 3,813 | | | 4,494 | |
Retail related | 3,248 | | | 4,121 | |
Other accrued expenses | 6,779 | | | 11,773 | |
Total accrued expenses | $ | 47,996 | | | $ | 58,222 | |
5. Income Taxes
The Company uses the estimated annual effective tax rate approach to determine the provision for income taxes. The estimated annual effective tax rate is based on forecasted annual results and may fluctuate due to differences between the forecasted and actual results, changes in valuation allowances, and any other transactions that result in differing tax treatment.
The Company's income tax expense and effective tax rate were as follows: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Income tax expense | $ | 261 | | | $ | 539 | |
Effective tax rate | (2.5) | % | | (1.6) | % |
The Company’s estimated annual effective income tax rate for the three months ended March 31, 2023 and 2022 differed from the statutory rate primarily due to the valuation allowance, non-deductible executive compensation, stock-based compensation, differences in tax rates in state and foreign jurisdictions, and other permanent items.
6. Stockholders’ Equity
Common Stock
As of March 31, 2023, the Company’s Twelfth Amended and Restated Certificate of Incorporation authorizes the issuance of up to 1,050,000,000 shares of common stock, par value of $0.0001 per share, of which 750,000,000 shares are designated Class A common stock, 150,000,000 shares are designated Class B common stock, and 150,000,000 shares are designated Class C common stock. Class A common stock receives one vote per share, Class B common stock receives ten votes per share, and Class C common stock has no voting rights except as required by Delaware law. Common stock is not redeemable at the option of the holder.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
As of March 31, 2023, outstanding shares of common stock as well as shares of common stock attributable to stock options, restricted stock units (“RSUs”), and performance stock units (“PSUs”) were as follows: | | | | | | | | | | | | | | | | | |
| Class A | | Class B | | Class C |
Common stock outstanding | 96,282,522 | | | 19,318,298 | | | — | |
Employee stock options – outstanding | 1,054,324 | | | 1,802,248 | | | — | |
Restricted stock units – outstanding | 2,901,351 | | | 1,956,310 | | | — | |
Performance stock units – outstanding | — | | | 4,397,688 | | | — | |
Employee stock plans – available | 25,309,009 | | | — | | | — | |
Shares of Class A common stock issuable upon conversion of all outstanding Class B common stock, options, RSUs, and PSUs | 27,474,544 | | | — | | | — | |
Total common stock – outstanding or issuable | 153,021,750 | | | 27,474,544 | | | — | |
Shares authorized | 750,000,000 | | | 150,000,000 | | | 150,000,000 | |
Common stock authorized and available for future issuance | 596,978,250 | | | 122,525,456 | | | 150,000,000 | |
| | | | | |
| | | | | |
Preferred Stock
As of March 31, 2023, 50,000,000 preferred shares were authorized and no shares were outstanding.
7. Stock-Based Compensation
Plans and Awards
The Company’s eligible employees participate in various stock-based compensation plans, which are provided by the Company directly.
In August 2021, the board of directors approved the 2021 Incentive Award Plan (the “2021 Plan”), which became effective on September 28, 2021, and the Company no longer grants equity awards under any prior equity plan. Upon the 2021 Plan becoming effective, there were 11,076,515 shares of Class A common stock authorized under the 2021 Plan, and the remaining shares available for issuance under the 2010 Equity Incentive Plan, 2011 Stock Plan, 2012 Milestone Stock Plan, and 2019 Founder Stock Plan (collectively, the “Prior Plans” and, collectively with the 2021 Plan, the “Plans”) were also made available for issuance under the 2021 Plan. The shares authorized under the 2021 Plan will increase annually, beginning on January 1, 2022 and continuing through 2031, by the lesser of (i) 5% of the outstanding common stock (on an as converted basis) as of the last day of the immediately preceding fiscal year, or (ii) a smaller amount as agreed by the board of directors. Awards granted under the 2021 Plan generally vest over four years. In addition, the shares authorized under the 2021 Plan will increase, among other things, to the extent that an award (including an award under the Prior Plans) terminates, expires, or lapses for any reason or an award is settled in cash without the delivery of shares. In January 2022, the board of directors approved an annual increase of 5,735,463 shares to the shares authorized for issuance under the 2021 Plan, and at December 31, 2022, 16,323,025 shares of Class A common stock remained available for future issuance pursuant to new awards under the 2021 Plan.
In January 2023, the board of directors approved an annual increase of 5,766,938 shares to the shares authorized for issuance under the 2021 Plan, and 20,981,889 shares remained available for future issuance pursuant to new awards as of March 31, 2023.
Employee Stock Purchase Plan
In August 2021, the board of directors adopted and the stockholders of the Company approved the 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP initially reserved and authorized the issuance of up to 2,215,303 shares of Class A common stock, and such reserve will be increased annually on the first day of each fiscal year beginning in 2022 and ending in 2031, by an amount equal to the lesser of (i) 1% of the shares of the Company’s common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the board of directors; provided, however, no more than 16,614,772 shares of common stock may be issued under the ESPP. In January 2022 and 2023, the board of directors approved an
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
annual increase of 1,147,092 and 1,153,387 shares, respectively, to the ESPP, and 4,327,120 shares remained available for future issuance pursuant to ESPP purchases as of March 31, 2023.
Offering periods begin on May 15 and November 15 of each year and consist of four six-month purchase periods. Eligible employees may contribute up to 20% of their base wages and the purchase price of shares of Class A common stock under an offering will be 85% of the lesser of the fair market value of Class A common stock on (i) the first day of the offering period, and (ii) the applicable purchase date. If such fair market value decreases from the first day of the offering period to the applicable purchase date, the offering period will terminate after the purchase of shares and all participants will be automatically enrolled in the next offering period (a “rollover event”).
During both the three months ended March 31, 2023 and 2022, zero shares were purchased under the ESPP. During the three months ended March 31, 2023 and 2022, the Company recognized $0.6 million and $0.5 million of stock-based compensation expense in connection with the ESPP, respectively, and withheld $0.6 million and $1.0 million of contributions from employees, respectively. As of March 31, 2023, total unrecognized compensation costs associated with the ESPP was $2.4 million and is expected to be amortized over a weighted average period of 0.6 years.
Stock-based Compensation Expense
Stock-based compensation expense consisted of the following: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Cost of goods sold | $ | 194 | | | $ | 226 | |
Selling, general, and administrative expenses | 19,586 | | | 26,918 | |
Total stock-based compensation expense | $ | 19,780 | | | $ | 27,144 | |
Stock-based compensation expense for the three months ended March 31, 2023 includes $13.8 million related to the 2021 Founders Grant, as described below, and $4.6 million in connection with RSUs. Stock-based compensation expense for the three months ended March 31, 2022 includes $20.1 million related to the 2021 Founders Grant, and $5.3 million in connection with RSUs.
Stock Options
The fair value for stock options and ESPP purchase rights granted under the Plans are estimated at the date of grant using the Black-Scholes option-pricing model. No options or ESPP purchase rights were granted during the three months ended March 31, 2023 and 2022.
Because the Company’s common stock was not yet publicly traded when the options currently outstanding were granted, the Company estimated the fair value of common stock. The board of directors considered numerous objective and subjective factors to determine the fair value of the Company’s common stock at each meeting in which awards are approved. The factors considered included, but were not limited to: (i) the results of contemporaneous independent third-party valuations of the Company’s common stock; (ii) the prices, rights, preferences, and privileges of the Company’s preferred stock relative to those of its common stock; (iii) the lack of marketability of the Company’s common stock; (iv) actual operating and financial results; (v) current business conditions and projections; (vi) the likelihood of achieving a liquidity event, such as a qualified public offering or sale of the Company, given prevailing market conditions; and (vii) contemporaneous transactions involving the Company’s common shares. The board of directors utilized third-party valuations which were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
A summary of stock option activity for the three months ended March 31, 2023 is as follows: | | | | | | | | | | | | | | | | | | | | | | | |
| Number of Stock Options | | Weighted Average Exercise Price | | Weighted average contractual term (years) | | Aggregate intrinsic value |
Balance at December 31, 2022 | 2,965,144 | | | $ | 7.23 | | | 4.5 | | $ | 21,243 | |
Options granted | — | | | — | | | | | |
Options exercised | (108,572) | | | 13.03 | | | | | 191 | |
Options forfeited | — | | | — | | | | | |
Balance at March 31, 2023 | 2,856,572 | | | $ | 7.01 | | | 4.2 | | $ | 14,886 | |
| | | | | | | |
Exercisable as of March 31, 2023 | 2,856,572 | | | $ | 7.01 | | | 4.2 | | $ | 14,886 | |
Vested as of March 31, 2023 | 2,336,998 | | | 4.73 | | | 3.5 | | |
Unvested as of March 31, 2023 | 519,574 | | | $ | 17.25 | | | 7.8 | | |
The total value of unrecognized stock compensation expense related to unvested options granted under the Plans was $4.8 million as of March 31, 2023, and is expected to be recognized over 0.8 years.
Restricted Stock Units and Performance Stock Units
A summary of RSU activity for the three months ended March 31, 2023 is as follows: | | | | | | | | | | | |
| Number of Restricted Stock Units | | Weighted Average Grant Date Fair Value |
Unvested as of December 31, 2022 | 3,314,420 | | | $ | 29.06 | |
Granted | 1,208,689 | | 13.91 | |
Forfeited | (100,615) | | 24.25 | |
Released | (153,474) | | 25.23 | |
Vested and not yet released | (133,256) | | 32.50 | |
Unvested as of March 31, 2023 | 4,135,764 | | | $ | 24.78 | |
The total value of unrecognized stock compensation expense related to outstanding RSUs and PSUs granted under the Plans was $62.6 million and $37.8 million as of March 31, 2023, respectively, which is expected to be recognized over a weighted-average period of 1.4 years and 0.8 years, respectively. No PSUs were granted, forfeited, released or vested during the three months ended March 31, 2023.
In June 2021, the Company granted 4,397,688 PSUs and 1,884,724 RSUs to the co-CEOs, in the aggregate, under the 2019 Founder Stock Plan (the “Founders Grant”). The PSUs vest upon two performance conditions, (i) a qualified public offering, which was satisfied upon the Company’s Direct Listing on September 20, 2021, and (ii) the price of the Company’s Class A common stock reaching stock price hurdles over a period of ten years, as defined by the terms of the award. The PSUs are subject to the co-CEOs’ continued employment with the Company through the applicable vesting date. If the PSUs vest, the Company will deliver one share of Class B common stock on the settlement date. Unvested PSUs expire in ten years from the date of grant. The terms of the PSUs granted are described further below.
The PSUs are divided into eight substantially equal tranches, each one vesting on the date the 90-day trailing volume-weighted average trading price of the Company’s Class A common stock exceeds the stock price hurdle, as
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
set forth in the table below, provided that no PSUs may vest prior to the six month anniversary of the Direct Listing. | | | | | | | | | | | | | | |
Tranche | | Number of PSUs | | Stock Price Hurdle |
1 | | 549,712 | | | $ | 47.75 | |
2 | | 549,710 | | | $ | 55.71 | |
3 | | 549,712 | | | $ | 63.67 | |
4 | | 549,710 | | | $ | 71.63 | |
5 | | 549,712 | | | $ | 79.59 | |
6 | | 549,710 | | | $ | 87.55 | |
7 | | 549,712 | | | $ | 95.50 | |
8 | | 549,710 | | | $ | 103.46 | |
The Company used a Monte Carlo simulation to calculate the grant-date fair value of the PSUs of $128.8 million. Since the PSUs contain a performance and market condition, the stock-based compensation expense will be recognized when it becomes probable that the performance condition will be met using the accelerated attribution method. Stock-based compensation will be recognized over the period of time the market condition for each tranche is expected to be met (i.e., the derived service period). The performance condition was satisfied at September 29, 2021 by the Direct Listing, and the Company began recording expense at that time.
The Founders Grant RSUs will vest in equal monthly installments over a period of five years, subject to the co-CEOs continued employment with the Company through the applicable vesting date and conditioned upon the completion of a qualified public offering. The grant-date fair value of the RSUs is $66.9 million. Since the RSUs contain a performance condition, stock-based compensation expense is recognized using the accelerated attribution method when it becomes probable that the performance condition will be met. The performance condition was satisfied on September 29, 2021 by the Direct Listing, and the Company began recording expense at that time.
Shares underlying vested PSUs and RSUs will be issued to the CEOs on a specified quarterly date following the second anniversary of the vesting date, except for an amount necessary to cover any taxes due in connection with the vesting, which will be withheld or sold to cover, or issued to offset, such taxes. Any RSUs or PSUs subject to the award that have not vested by the tenth anniversary of the grant date will be forfeited.
RSUs granted prior to the Company’s direct listing vest upon the satisfaction of both a service and a performance condition. Prior to its direct listing, the Company had concluded that it was not probable that the performance condition would be satisfied as the closing of a qualified public offering or change in control is not deemed probable until consummated. Upon its direct listing on September 29, 2021, the Company recorded stock-based compensation expense for the service condition satisfied through such date and began recording stock-based compensation expense using the accelerated attribution method as the service conditions are met. RSUs issued after its direct listing only contain a service condition and are recognized on a straight line basis over the vesting period.
8. Leases
The Company leases retail, office, optical laboratory, and distribution center space under operating leases from third parties. As of March 31, 2023, the total lease terms of the various leases range from 3 to 18 years. The leases generally contain renewal options and rent escalation clauses, and from time to time include contingent rent provisions. Renewal options are exercisable at the Company’s sole discretion and are included in the lease term if they are reasonably certain to be exercised. In general it is not reasonably certain that lease renewals will be exercised at lease commencement and as such, lease renewals are not included in the lease term. The Company’s finance leases are immaterial.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
The following table presents the assets and liabilities related to the Company’s leases:
| | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 |
Lease assets: | | | |
Right-of-use assets | $ | 123,278 | | | $ | 127,014 | |
Total lease assets | 123,278 | | | 127,014 | |
| | | |
Lease liabilities: | | | |
Current lease liabilities | 21,710 | | | 22,546 | |
Non-current lease liabilities | 148,922 | | | 150,832 | |
Total lease liabilities | $ | 170,632 | | | $ | 173,378 | |
The following table details the Company’s net lease expense: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Operating lease expense | $ | 7,436 | | | $ | 6,013 | |
Variable lease expense(1) | 743 | | | 938 | |
Net lease expense | $ | 8,179 | | | $ | 6,951 | |
(1) Variable lease expense primarily consists of contingent rent.
The following table presents the future maturity of lease liabilities: | | | | | |
| Operating Leases(1) |
2023 | $ | 20,998 | |
2024 | 37,099 | |
2025 | 32,337 | |
2026 | 30,724 | |
2027 | 27,431 | |
Thereafter | 50,154 | |
Future minimum lease payments | 198,743 | |
Impact of discounting | 28,111 | |
Present value of lease payments | $ | 170,632 | |
(1) The year 2023 and 2024 includes $7.2 million and $2.4 million, respectively, of expected cash inflows from TIAs. Operating lease payments exclude $7.5 million of legally binding minimum lease payments related to executed leases for which the Company has not yet taken possession of the leased premises.
The following table presents other relevant lease information: | | | | | |
| March 31, 2023 |
Weighted average remaining lease term (years) | 5.9 |
Weighted average discount rate | 4.5 | % |
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
9. Commitments and Contingencies
2013 Credit Facility
In August 2013, the Company entered into a Loan and Security Agreement with Comerica Bank (as amended, the “2013 Credit Facility”), which consisted of a revolving credit line of up to $50.0 million with a sub-limit of $15.0 million for the issuance of letters of credit. Borrowings under the revolving credit line bore interest on the principal amount outstanding at a variable interest rate based on either LIBOR or the bank’s prime rate, with no additional margin. The Company was charged fees on the uncommitted portion of the credit line of approximately 0.2% as long as total borrowings were less than $15.0 million. The 2013 Credit Facility was replaced by the 2022 Credit Facility (as defined below).
2022 Credit Facility
In September 2022, the Company and its wholly owned subsidiary, Warby Parker Retail, Inc., (together, the "Borrowers") entered into a Credit Agreement with Comerica Bank and the lenders from time to time party thereto (as amended, the "2022 Credit Facility"), which replaced the 2013 Credit Facility. The 2022 Credit Facility consists of a $100.0 million five-year revolving credit facility with sublimits of $15.0 million for letters of credit and $5.0 million for swing line notes. The 2022 Credit Facility includes an option for the Company to increase the available amount by up to $75.0 million, for a maximum borrowing capacity of $175.0 million, subject to the consent of the lenders funding the increase and certain other conditions. Proceeds of the borrowings under the 2022 Credit Facility are expected to be used for working capital and other general corporate purposes in the ordinary course of business. The Company is permitted to repay borrowings under the 2022 Credit Facility at any time, in whole or in part, without penalty.
Under the 2022 Credit Facility, borrowings bear interest on the principal amount outstanding at a variable interest rate either (a) based on the greater of (1) the prime rate (as defined in the credit agreement), (2) the federal funds rate plus 1%, and (3) the Bloomberg Short-Term Bank Yield Index rate (“BSBY Rate”) for a one month tenor plus 1%, in each case plus an applicable margin of 0.5% - 0.8% depending on the Company’s leverage ratio, or (b) the BSBY Rate plus an applicable margin of 1.5% - 1.8% depending on the Company’s leverage ratio. The Company is charged commitment fees of 0.15% whether or not amounts have been borrowed. Both interest on principal and commitment fees are included in interest expense on the condensed consolidated statements of operations.
The 2022 Credit Facility contains a financial maintenance covenant which takes effect once total borrowings first exceed $60.0 million, and at all times thereafter, that requires the Company to maintain a maximum consolidated senior net leverage ratio of 3:1. The 2022 Credit Facility contains customary affirmative and negative covenants, including limits on indebtedness, liens, capital expenditures, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets, as well as representations, warranties and event of default provisions. The obligations of the Borrowers under the Credit Agreement are secured by first-lien security interests in substantially all of the assets of the Borrowers. In addition, the obligations are required to be guaranteed in the future by certain additional domestic subsidiaries of the Company.
Other than letters of credit outstanding of $4.2 million as of both March 31, 2023 and December 31, 2022, respectively, used to secure certain leases in lieu of a cash security deposit, there were no other borrowings outstanding under the 2022 Credit Facility or 2013 Credit Facility.
Litigation
During the normal course of business, the Company may become subject to legal proceedings, claims and litigation. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated.
As of March 31, 2023, the Company is not subject to any pending legal matters or claims that could have a material adverse effect on its financial position, results of operations, or cash flows should such litigation be resolved unfavorably.
Warby Parker Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Amounts in thousands, except share data)
10. Net Loss Per Share Attributable to Common Stockholders
The computation of net loss per share attributable to common stockholders is as follows: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Numerator | | | |
Net loss attributable to common stockholders - basic and diluted | $ | (10,812) | | | $ | (34,133) | |
Denominator | | | |
Weighted average shares, basic and diluted | 116,159,428 | | | 114,103,766 | |
Earnings Per Share | | | |
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.09) | | | $ | (0.30) | |
The following potentially dilutive shares were excluded from the computation of diluted net loss per share because including them would have been antidilutive: | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Stock options to purchase common stock | 2,856,572 | | | 3,423,813 | |
Unvested restricted stock units | 4,135,764 | | | 3,265,465 | |
Unvested performance stock units | 4,397,688 | | | 4,397,688 | |
ESPP purchase rights | 376,493 | | | 177,113 | |
11. Related-Party Transactions
As a private company, the Company issued secured promissory notes collateralized by the stock purchased by certain Company executives in relation to the exercise of employee stock options. As the promissory notes are secured by the underlying shares they have been treated as non-recourse notes in the condensed consolidated financial statements. The promissory notes were issued with a term of 8.5 years and an interest rate equal to the minimum applicable federal mid-term rate in the month the loan was issued. The secured promissory notes were recorded as a reduction to equity offsetting the amount in additional paid-in-capital related to the exercised options funded by the notes.
The loans are held by current and former employees and had a balance of $2.5 million at both March 31, 2023 and December 31, 2022. No loans are outstanding with any of our executive officers.
During both the three months ended March 31, 2023 and 2022, the outstanding loan balance increased by an immaterial amount due to interest. No new promissory notes were issued during the three months ended March 31, 2023 and 2022.
12. Subsequent Events
Lease Obligations
Subsequent to March 31, 2023, the Company entered into 3 operating lease agreements for retail space in the U.S., with terms ranging from 5 to 7 years. Total commitments under the new agreements are approximately $1.6 million, payable over the terms of the related agreements.
Equity Awards
In April 2023, the board of directors approved grants of 178,299 RSUs for Class A common stock to employees under the 2021 Plan. The total grant date fair value of these awards was $2.0 million and will be recognized as stock-based compensation, net of forfeitures as incurred, over approximately four years.
Item 2. Management’s Discussion And Analysis Of Financial Condition And Results Of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 (the “Annual Report”). Data as of and for the three months ended March 31, 2023 and 2022 has been derived from our unaudited condensed consolidated financial statements. Results for any interim period should not be construed as an inference of what our results would be for any full fiscal year or future period. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, such as those relating to our plans, objectives, expectations, intentions, and beliefs, which involve risks and uncertainties. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled “Special Note Regarding Forward-Looking Statements” in this Quarterly Report on Form 10-Q and in Part I, Item 1A, Risk Factors, in the Annual Report.
Overview
A pioneer of the direct-to-consumer model, Warby Parker is one of the fastest-growing brands at scale in the United States. We are a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise.
Since day one, our focus on delighting customers and doing good has created a foundation for continuous innovation:
•We aim to provide customers with the highest-quality product possible by designing glasses at our headquarters in New York City, using custom materials, and selling direct to the customer. By cutting out the middleman, we are able to sell our products at a lower price than many of our competitors and pass the savings on to our customers. In addition to lower prices, we introduced simple, unified pricing (glasses starting at $95, including prescription lenses) to the eyewear market.
•We’ve built a seamless shopping experience that meets customers where and how they want to shop, whether that’s on our website, on our mobile app, or in our 204 retail stores.
•We’ve crafted a holistic vision care offering that extends beyond glasses to include contacts, vision tests and eye exams, vision insurance, and beyond. We leverage leading (and in many cases proprietary) technology to enhance our customers’ experiences, whether it’s to help them find a better-fitting frame using our Virtual Try-On tool, or to update their prescription from home using Virtual Vision Test, our telehealth app.
•We recruit and retain highly engaged, motivated team members who are driven by our commitment to scaling a large, growing business while making an impact and are excited to connect their daily work back to our mission.
•We are a public benefit corporation focused on positively impacting all stakeholders, and hope to inspire other entrepreneurs and businesses to think along the same lines. Working closely with our nonprofit partners, we distribute glasses to people in need in more than 50 countries globally and many parts of the United States. Over 13 million more people now have the glasses they need to learn, work, and achieve better economic outcomes through our Buy a Pair, Give a Pair program.
We generate revenue through selling our wide array of prescription and non-prescription eyewear, including glasses, sunglasses, and contact lenses. We also generate revenue from providing eye exams and vision tests, and selling eyewear accessories. We maintain data across the entire customer journey that allows us to develop deep insights, informing our innovation priorities and enabling us to create a highly personalized, brand-enhancing experience for our customers. We have built an integrated, multichannel presence that we believe deepens our relationship with existing customers while broadening reach and accessibility. And while we have the ability to track where our customers transact, we’re channel agnostic to where the transaction takes place and find that many of our customers engage with us across both digital and physical channels; for example, many customers who check out online also visit a store throughout their customer journey, while others choose to browse online before visiting one of our stores.
Financial Highlights
For the three months ended March 31, 2023 and 2022:
•we generated net revenue of $172.0 million and $153.2 million, respectively;
•we generated gross profit of $94.8 million and $89.6 million, respectively, representing a gross profit margin of 55.1% and 58.5%, respectively;
•we generated net loss of $10.8 million and $34.1 million, respectively; and
•we generated adjusted EBITDA of $17.7 million and $0.8 million, respectively.
For a definition of adjusted EBITDA, a non-GAAP measure, and a reconciliation to the most directly comparable GAAP measure, see the section titled “Key Business Metrics and Certain Non-GAAP Financial Measures.”
Factors Affecting Our Financial Condition and Results of Operations
We believe that our performance and future success depend on a variety of factors that present significant opportunities for our business but also present risks and challenges that could adversely impact our growth and profitability, including those discussed below and in Part I, Item 1A. “Risk Factors” of the Annual Report.
Overall economic environment
The nature of our business, which involves the sale of products and services that are a medical necessity for many consumers, provides some insulation from swings in consumer sentiment and general economic conditions. However, our performance and growth are still impacted by these factors. The current economic downturn, rising inflation and interest rates, and other negative economic factors may impact consumer spending habits as well as our cost of attracting and our ability to attract new customers. For example, during the first quarter of 2023, we continued to see lower overall sales growth rates than we have historically experienced as consumer activity within the optical industry has not recovered to pre-pandemic growth levels and is expected to remain flat in 2023 based on The Vision Council’s projections. We believe our business model, focused on providing an exceptional value and experience to our customers, will help mitigate the impact of many of these macroeconomic factors, however, the extent of such mitigation and the impact on future results is uncertain. We also continue to diversify and expand our supply chain network, both internationally with our frame manufacturers and domestically with our wholly owned and partner optical laboratories, which we believe has helped to insulate us from supply chain disruption and allowed us to continue to meet growing customer demand over the last several years while maintaining our exceptional quality and customer satisfaction standards.
Key Business Metrics and Certain Non-GAAP Financial Measures
In addition to the measures presented in our condensed consolidated financial statements, we use the following key business metrics and certain non-GAAP financial measures to evaluate our business, measure our performance, develop financial forecasts, and make strategic decisions. The following table summarizes our key performance indicators and non-GAAP financial measures for each period presented below, which are unaudited.
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
Active Customers (in millions) | 2.29 | | | 2.23 | |
Store Count(1) | 204 | | | 169 | |
Adjusted EBITDA(2) (in thousands) | $ | 17,738 | | | $ | 774 | |
Adjusted EBITDA margin(2) | 10.3 | % | | 0.5 | % |
__________________
(1)Store Count number at the end of the period indicated.
(2)Adjusted EBITDA and adjusted EBITDA margin are supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. Adjusted EBITDA and adjusted EBITDA margin are not measurements of our financial performance under GAAP and should not be considered as an alternative to net loss or any other performance measure derived in accordance with GAAP.
Active Customers
The number of Active Customers is a key performance measure that we use to assess the reach of our physical retail stores and digital platform as well as our brand awareness. We define an Active Customer as a unique customer that has made at least one purchase in the preceding 12-month period. We determine our number of Active Customers by counting the total number of customers who have made at least one purchase in the preceding 12-month period,
measured from the last date of such period. Given our definition of a customer is a unique customer that has made at least one purchase, it can include either an individual person or a household of more than one person utilizing a single account.
Store Count
Store Count is a key performance measure that we use to reach consumers and generate incremental demand for our products. We define Store Count as the total number of retail stores open at the end of a given period. We believe our retail stores embody our brand, drive brand awareness, and serve as efficient customer acquisition vehicles. Our results of operations have been and will continue to be affected by the timing and number of retail stores that we operate.
As of March 31, 2023, 155 out of our 204 retail stores offered in-person eye exams.
Adjusted EBITDA and Adjusted EBITDA Margin
We define adjusted EBITDA as net income (loss) before interest and other income, taxes, and depreciation and amortization as further adjusted for asset impairment costs, stock-based compensation expense and related employer payroll taxes, amortization of cloud-based software implementation costs, non-cash charitable donations, and non-recurring costs such as restructuring costs, major system implementation costs, and direct listing or other transaction costs. We define adjusted EBITDA margin as adjusted EBITDA divided by net revenue. We caution investors that amounts presented in accordance with our definitions of adjusted EBITDA and adjusted EBITDA margin may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate adjusted EBITDA and adjusted EBITDA margin in the same manner. We present adjusted EBITDA and adjusted EBITDA margin because we consider these metrics to be important supplemental measures of our performance and believe they are frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Management believes that investors’ understanding of our performance is enhanced by including these non-GAAP financial measures as a reasonable basis for comparing our ongoing results of operations.
Management uses adjusted EBITDA and adjusted EBITDA margin:
•as a measurement of operating performance because they assist us in evaluating the operating performance of our business on a consistent basis, as they remove the impact of items not directly resulting from our core operations;
•for planning purposes, including the preparation of our internal annual operating budget and financial projections;
•to evaluate the performance and effectiveness of our operational strategies; and
•to evaluate our capacity to expand our business.
By providing these non-GAAP financial measures, together with a reconciliation to the most directly comparable GAAP measure, we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA and adjusted EBITDA margin have limitations as analytical tools, and should not be considered in isolation, or as an alternative to, or a substitute for net loss or other financial statement data presented in our condensed consolidated financial statements as indicators of financial performance. Some of the limitations are:
•such measures do not reflect our cash expenditures, or future requirements for capital expenditures, or contractual commitments;
•such measures do not reflect changes in, or cash requirements for, our working capital needs;
•such measures do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments on our debt;
•such measures do not reflect our tax expense or the cash requirements to pay our taxes;
•although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future and such measures do not reflect any cash requirements for such replacements; and
•other companies in our industry may calculate such measures differently than we do, limiting their usefulness as comparative measures.
Due to these limitations, adjusted EBITDA and adjusted EBITDA margin should not be considered as measures of discretionary cash available to us to invest in the growth of our business. We compensate for these limitations by
relying primarily on our GAAP results and using these non-GAAP measures only supplementally. Each of the adjustments and other adjustments described in this paragraph and in the reconciliation table below help management with a measure of our core operating performance over time by removing items that are not related to day-to-day operations.
The following table reconciles adjusted EBITDA and adjusted EBITDA margin to the most directly comparable GAAP measure, which is net loss:
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2023 | | 2022 |
| (in thousands) |
Net loss | $ | (10,812) | | | $ | (34,133) | |
Adjusted to exclude the following: | | | |
Interest and other loss, net | (1,878) | | | (146) | |
Provision for income taxes | 261 | | | 539 | |
Depreciation and amortization expense | 9,140 | | | 6,910 | |
Asset impairment charges | 395 | | | 227 | |
Stock-based compensation expense(1) | 19,866 | | | 27,377 | |
Amortization of cloud-based software implementation costs(2) | 363 | | | — | |
ERP implementation costs(3) | 403 | | | — | |
Adjusted EBITDA | 17,738 | | | 774 | |
Adjusted EBITDA margin | 10.3 | % | | 0.5 | % |
__________________(1) Represents expenses related to the Company’s equity-based compensation programs and related employer payroll taxes, which may vary significantly from period to period depending upon various factors including the timing, number, and the valuation of awards granted, and vesting of awards including the satisfaction of performance conditions. For the three months ended March 31, 2023 and 2022, the amount includes $0.1 million and $0.2 million, respectively, of employer payroll costs associated with releases of RSUs and option exercises.
(2) Represents the amortization of costs capitalized in connection with the implementation of cloud-based software.
(3) Represents internal and external non-capitalized costs related to the implementation of our new Enterprise Resource Planning (“ERP”) system.
Results of Operations
The results of operations presented below should be reviewed in conjunction with the condensed consolidated financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q. The following tables set forth our results of operations for the periods presented in dollars and as a percentage of net revenue:
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2023 | | 2022 | | | | |
| (in thousands) | | |
Condensed Consolidated Statements of Operations Data: | | | | | | | |
Net revenue | $ | 171,968 | | | $ | 153,218 | | | | | |
Cost of goods sold | 77,177 | | | 63,572 | | | | | |
Gross profit | 94,791 | | | 89,646 | | | | | |
Selling, general, and administrative expenses | 107,221 | | | 123,386 | | | | | |
Loss from operations | (12,430) | | | (33,740) | | | | | |
Interest and other income, net | 1,879 | | | 146 | | | | | |
Loss before income taxes | (10,551) | | | (33,594) | | | | | |
Provision for income taxes | 261 | | | 539 | | | | | |
Net loss | (10,812) | | | (34,133) | | | | | |
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2023 | | 2022 | | | | |
| % of Net Revenue | | |
Condensed Consolidated Statements of Operations Data: | | | | | | | |
Net revenue | 100.0 | % | | 100.0 | % | | | | |
Cost of goods sold | 44.9 | % | | 41.5 | % | | | | |
Gross profit | 55.1 | % | | 58.5 | % | | | | |
Selling, general, and administrative expenses | 62.3 | % | | 80.5 | % | | | | |
Loss from operations | (7.2) | % | | (22.0) | % | | | | |
Interest and other income, net | 1.1 | % | | 0.1 | % | | | | |
Loss before income taxes | (6.1) | % | | (21.9) | % | | | | |
Provision for income taxes | 0.2 | % | | 0.4 | % | | | | |
Net loss | (6.3) | % | | (22.3) | % | | | | |
Components of Results of Operations
Net Revenue
We primarily derive revenue from the sales of eyewear products, optical services, and accessories. We sell products and services through our retail stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges, which are charged to the customer, associated with these purchases. Revenue is recognized when the customer takes possession of the product, either at the point of delivery or in-store pickup, and is recorded net of returns and discounts. Revenue generated from services consists of both in-person eye exams and prescriptions issued through the Virtual Vision Test app. Revenue is recognized when the service is rendered and is recorded net of discounts.
Cost of Goods Sold
Cost of goods sold includes the costs incurred to acquire materials, assemble, and sell our finished products. Such costs include (i) product costs held at the lesser of cost and net realizable value, (ii) freight and import costs, (iii) optical laboratory costs, (iv) customer shipping, (v) occupancy and depreciation costs of retail stores, and (vi) employee-related costs associated with our prescription services and optical laboratories, which includes salaries, benefits, bonuses, and stock-based compensation. We expect our cost of goods sold to fluctuate as a percentage of net revenue primarily due to product mix, customer preferences and resulting demand, customer shipping costs, and management of our inventory and merchandise mix. Cost of goods sold also may change as we open or close retail stores because of the resulting change in related occupancy and depreciation costs. Over time we expect our cost of goods sold to increase with revenue due to an increased number of orders and with the opening of new retail stores driven by the resulting occupancy and depreciation costs and employee-related costs associated with prescription services offerings at our retail stores.
Gross Profit and Gross Margin
We define gross profit as net revenues less cost of goods sold. Gross margin is gross profit expressed as a percentage of net revenues. Our gross margin has remained relatively steady historically, but has decreased as we have expanded our holistic eyecare offering with contacts and eye exams which operate at a lower margin than eyeglasses. Gross margin may continue to fluctuate in the future based on a number of factors, including the cost at which we can obtain, transport, and assemble our inventory, the rate at which we open new retail stores, the mix of products we sell, and how effective we can be at controlling costs, in any given period.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses, or SG&A, primarily consist of employee-related costs including salaries, benefits, bonuses, and stock-based compensation for our corporate and retail employees, marketing, information technology, credit card processing fees, donations in connection with our Buy a Pair, Give a Pair program, facilities, legal, and other administrative costs associated with operating the business. Marketing costs, which consist of both online and offline advertising, include sponsored search, online advertising, marketing and retail events, and other
initiatives. SG&A also includes administrative costs associated with our Home Try-On program, which provides customers the opportunity to sample eyewear at home prior to purchase. SG&A is expensed in the period in which it is incurred. During 2022 we implemented a headcount reduction in our corporate offices and are executing on certain other cost control actions, including reducing marketing spend and other variable costs. We expect these actions to reduce costs included in SG&A, however, the changing prices of goods and services caused by inflation and other macroeconomic factors may cause unforeseen fluctuations in SG&A expenses.
Interest and Other Income, Net
Interest and other income, net, consists primarily of interest generated from our cash and cash equivalents balances net of interest incurred on borrowings and fees on our undrawn line of credit, and are recognized as incurred. We expect our interest and other income costs to fluctuate based on our future bank balances, credit line utilization, and the interest rate environment.
Provision for Income Taxes
Provision for income taxes consists of income taxes related to foreign and domestic federal and state jurisdictions in which we conduct business, adjusted for allowable credits, deductions, and valuation allowance against deferred tax assets.
Comparison of the Three Months Ended March 31, 2023 and 2022
Net Revenue
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | |
| 2023 | | 2022 | | $ Change | | % Change |
| (in thousands) | | | | |
Net revenue | $ | 171,968 | | | $ | 153,218 | | | $ | 18,750 | | | 12.2 | % |
Net revenue increased $18.8 million, or 12.2%, for the three months ended March 31, 2023 compared to the same period in 2022. The growth in net revenue was driven by an increase in Average Order Value (“AOV”), which is defined as net revenue for a given period divided by the number of orders during the same period, as well as an increase in our Active Customer base. The increase in AOV was driven by an increase in our average units per order.
Cost of Goods Sold, Gross Profit, and Gross Margin
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | |
| 2023 | | 2022 | | $ Change | | % Change |
| (in thousands) | | | | |
Cost of goods sold | $ | 77,177 | | | $ | 63,572 | | | $ | 13,605 | | | 21.4 | % |
Gross profit | 94,791 | | | 89,646 | | | 5,145 | | | 5.7 | % |
Gross margin | 55.1 | % | | 58.5 | % | | | | (3.4) | % |
Cost of goods sold increased by $13.6 million, or 21.4%, for the three months ended March 31, 2023 compared to the same period in 2022, and increased as a percentage of revenue over the same period by 340 basis points, from 41.5% of revenue to 44.9% of revenue. The increase in cost of goods sold was primarily driven by increased product and fulfillment costs associated with our sales growth, particularly related to the growth in our contact lens offering, as well as increases in store occupancy, store depreciation, and prescription services expenses due to new retail stores opened in 2023 and a full period of expense from new retail stores opened throughout 2022.
Gross profit, calculated as net revenue less cost of goods sold, increased by $5.1 million, or 5.7%, for the three months ended March 31, 2023 compared to the same period in 2022, primarily due to the increase in net revenue over the same period.
Gross margin, expressed as a percentage and calculated as gross profit divided by net revenue, decreased by 340 basis points for the three months ended March 31, 2023 compared to the same period in 2022. The decrease in gross margin was primarily driven by increases in store occupancy costs as a percent of revenue primarily due to increased depreciation and rent charges as we grew our store base from 169 stores as of March 31, 2022 to 204 stores as of
March 31, 2023, increased prescription services costs as the number of stores with optical examination rooms grew, and the sales growth of contact lenses which are sold at a lower margin than our other eyewear.
Selling, General, and Administrative Expenses
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | |
| 2023 | | 2022 | | $ Change | | % Change |
| (in thousands) | | | | |
Selling, general, and administrative expenses | $ | 107,221 | | | $ | 123,386 | | | $ | (16,165) | | | (13.1) | % |
As a percentage of net revenue | 62.3 | % | | 80.5 | % | | | | (18.2) | % |
Selling, general, and administrative expenses decreased $16.2 million, or 13.1%, for the three months ended March 31, 2023 compared to the same period in 2022. This decrease was primarily driven by lower marketing costs, including costs associated with our Home Try-On program, which decreased to 12% of revenue in the current quarter compared to 20% in the same quarter of 2022, and a $7.4 million decrease in stock-based compensation, mostly related to the Founders Grant (as described in Note 7 to our condensed consolidated financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q). The decrease was partially offset by increased compensation costs, mainly from growth in our retail workforce and increased depreciation and amortization costs, mainly related to capitalized software and office build outs.
Interest and Other Income, Net
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | |
| 2023 | | 2022 | | $ Change | | % Change |
| (in thousands) | | | | |
Interest and other income, net | $ | 1,879 | | | $ | 146 | | | $ | 1,733 | | | 1187.0 | % |
As a percentage of net revenue | 1.1 | % | | 0.1 | % | | | | 1.0 | % |
Interest and other income, net increased $1.7 million, or 1,187.0%, for the three months ended March 31, 2023 compared to the same period in 2022 primarily due to higher interest rates on our cash balance.
Provision for Income Taxes
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | |
| 2023 | | 2022 | | $ Change | | % Change |
| (in thousands) | | | | |
Provision for income taxes | $ | 261 | | | $ | 539 | | | $ | (278) | | | (51.6) | % |
As a percentage of net revenue | 0.2 | % | | 0.4 | % | | | | (0.2) | % |
Provision for income taxes decreased $0.3 million, or 51.6%, for the three months ended March 31, 2023 compared to the same period in 2022 primarily due to the change in pre-tax loss in addition to the tax effects of stock-based compensation expense and the establishment of a valuation allowance.
Seasonality
Historically, we have observed moderately higher seasonal demand during the month of December due in part to customer usage of health and flexible spending benefits in the final week of the year. Consistent with our policy to recognize revenue upon order delivery, any orders placed at the end of December are recognized as revenue upon delivery, which may occur in the following year, and as such we typically see revenue increase sequentially from the fourth quarter to the first quarter of the following year.
Our business has historically experienced a higher proportion of costs in each subsequent quarter as a year progresses due to the overall growth of the business and operating costs to support that growth, including costs related to the opening of new retail stores and employee-related compensation to support growth. The fourth quarter, in particular, has historically experienced the highest amount of costs in a year to support the business demand in the quarter, even though a portion of the net revenue from that demand is not recognized until January of the following
year, as discussed above. In 2022, this historical trend was offset by specific actions we took to reduce costs, including a reduction in marketing spend beginning in the second quarter and a reduction in corporate headcount in connection with our restructuring plan that was executed in the third quarter. These actions contributed to a sequential decline in selling, general, and administrative costs from quarter to quarter in 2022, however, we expect 2023 to follow historic trends. In the future, seasonal trends may cause fluctuations in our quarterly results, which may impact the predictability of our business and operating results.
Liquidity and Capital Resources
Since inception, we have financed our operations primarily from net proceeds from the sale of redeemable convertible preferred stock and cash flows from operating activities. As of March 31, 2023, we had cash and cash equivalents of $204.3 million, which was primarily held for working capital purposes, and an accumulated deficit of $614.4 million. As of December 31, 2022, we had cash and cash equivalents of $208.6 million, which was primarily held for working capital purposes, and an accumulated deficit of $603.6 million.
We expect that operating losses could continue in the foreseeable future as we continue to invest in the expansion of our business. We believe our existing cash and cash equivalents, funds available under our existing credit facility, and cash flows from operating activities will be sufficient to fund our operations for at least the next 12 months.
However, our future capital requirements will depend on many factors, including, but not limited to, growth in the number of retail stores, the needs of our optical laboratories and distribution network, expansion of our product offerings or service capabilities, and the timing of investments in technology and personnel to support the overall growth in our business. To the extent that current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may be required to seek additional equity or debt financing. The sale of additional equity would result in dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for additional operating and financing covenants that would restrict our operations. There can be no assurances that we will be able to raise additional capital. In the event that additional financing is required from outside sources, we may not be able to negotiate terms acceptable to us or at all. In particular, the COVID-19 pandemic, rising interest and inflation rates, and other macroeconomic factors have caused disruption in the global financial markets, which could reduce our ability to access capital and negatively affect our liquidity in the future. If we are unable to raise additional capital when required, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, financial condition, and cash flows would be adversely affected.
Credit Facility
2013 Credit Facility
In August 2013, the Company entered into a Loan and Security Agreement with Comerica Bank (as amended, the “2013 Credit Facility”), which consisted of a revolving credit line of up to $50.0 million with a sub-limit of $15.0 million for the issuance of letters of credit. Borrowings under the revolving credit line bore interest on the principal amount outstanding at a variable interest rate based on either LIBOR or the bank’s prime rate, with no additional margin. The Company was charged fees on the uncommitted portion of the credit line of approximately 0.2% as long as total borrowings were less than $15.0 million. The 2013 Credit Facility was replaced by the 2022 Credit Facility (as defined below).
2022 Credit Facility
In September 2022, the Company and its wholly owned subsidiary, Warby Parker Retail, Inc., entered into a Credit Agreement with Comerica Bank and the lenders from time to time party thereto (as amended, the “2022 Credit Facility”), which replaced the 2013 Credit Facility. The 2022 Credit Facility consists of a $100.0 million five-year revolving credit facility with sublimits of $15.0 million for letters of credit and $5.0 million for swing line notes. The 2022 Credit Facility includes an option for the Company to increase the available amount by up to $75.0 million, for a maximum borrowing capacity of $175.0 million, subject to the consent of the lenders funding the increase and certain other conditions. Proceeds of the borrowings under the 2022 Credit Facility are expected to be used for working capital and other general corporate purposes in the ordinary course of business. The Company is permitted to repay borrowings under the 2022 Credit Facility at any time, in whole or in part, without penalty.
Under the 2022 Credit Facility, borrowings under the revolving credit facility bear interest on the principal amount outstanding at a variable interest rate either (a) based on the greater of (1) the prime rate (as defined in the credit agreement), (2) the federal funds rate plus 1%, and (3) the Bloomberg Short-Term Bank Yield Index rate (“BSBY Rate”)
for a one month tenor plus 1%, in each case plus an applicable margin of 0.5% - 0.8% depending on the Company’s leverage ratio, or (b) the BSBY Rate plus an applicable margin of 1.5 - 1.8% depending on the Company’s leverage ratio. The Company is charged commitment fees of 0.15% whether or not amounts have been borrowed. Both interest on principal and commitment fees are included in interest expense on the condensed consolidated statements of operations.
The 2022 Credit Facility contains a financial maintenance covenant which takes effect once total borrowings first exceed $60.0 million, and at all times thereafter, which requires the Company to maintain a maximum consolidated senior net leverage ratio of 3:1. The 2022 Credit Facility contains customary affirmative and negative covenants, including limits on indebtedness, liens, capital expenditures, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets, as well as representations, warranties and event of default provisions. The obligations of the Borrowers under the Credit Agreement are secured by first-lien security interests in substantially all of the assets of the Borrowers. In addition, the obligations are required to be guaranteed in the future by certain additional domestic subsidiaries of the Company.
Other than letters of credit outstanding of $4.2 million as of both March 31, 2023 and December 31, 2022, used to secure certain leases in lieu of a cash security deposit, there were no other borrowings outstanding under the 2022 Credit Facility or 2013 Credit Facility.
Cash Flows
The following table summarizes our cash flows for the three months ended March 31, 2023 and 2022:
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2023 | | 2022 | | | | |
| (in thousands) | | | | |
Net cash provided by (used in) operating activities | $ | 8,643 | | | $ | (10,296) | | | | | |
Net cash used in investing activities | (12,385) | | | (16,060) | | | | | |
Net cash provided by financing activities | 81 | | | 180 | | | | | |
Effect of exchange rates on cash | (662) | | | 84 | | | | | |
Net decrease in cash and cash equivalents | $ | (4,323) | | | $ | (26,092) | | | | | |
Cash Flows from Operating Activities
Net cash provided by operating activities was $8.6 million for the three months ended March 31, 2023, consisting of a net loss of $10.8 million adjusted for $29.7 million of non-cash expenses and $10.3 million of net cash used as a result of changes in operating assets and liabilities. The non-cash charges included $19.8 million of stock-based compensation, $9.1 million of depreciation and amortization, $0.4 million of asset impairment charges, and $0.4 million of amortization of cloud-based software implementation costs. The changes in operating assets and liabilities were primarily driven by a decrease in accrued expenses and deferred revenue, partially offset by decreases in inventory and prepaid expenses and other current assets.
Net cash used in operating activities was $10.3 million for the three months ended March 31, 2022, consisting of a net loss of $34.1 million, adjusted for $34.3 million of non-cash expenses and $10.5 million of net cash used as a result of changes in operating assets and liabilities. The non-cash charges included $27.1 million of stock-based compensation, $6.9 million of depreciation and amortization, and $0.2 million of asset impairment charges. The changes in operating assets and liabilities were primarily driven by increases in accrued expenses, accounts payable, and deferred rent, partially offset by an increase in net inventory to support the growth of our business and decreases in deferred revenue.
Cash Flows from Investing Activities
For the three months ended March 31, 2023, net cash used in investing activities was $12.4 million related to purchases of property and equipment to support our growth, primarily related to the build-out of new retail stores, as well as investments in capitalized software development costs.
For the three months ended March 31, 2022, net cash used in investing activities was $16.1 million related to purchases of property and equipment to support our growth, primarily related to the build-out of new retail stores, as well as investments in capitalized software development costs.
Cash Flows from Financing Activities
For the three months ended March 31, 2023, net cash provided by financing activities was $0.1 million, which was primarily related to proceeds from stock option exercises.
For the three months ended March 31, 2022, net cash provided by financing activities was $0.2 million, which was primarily related to proceeds from stock option exercises.
Contractual Obligations and Commitments
There have been no material changes to our contractual obligations from those described in the Annual Report.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q are prepared in accordance with GAAP. The preparation of condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ significantly from our estimates. To the extent that there are differences between our estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected.
Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” in the Annual Report and the notes to the audited consolidated financial statements appearing elsewhere in the Annual Report, and in Note 2 to our condensed consolidated financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q. There were no significant changes to our critical accounting policies and estimates as reported in the Annual Report.
Recent Accounting Pronouncements
See Note 2 to our condensed consolidated financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q for more information regarding recent accounting pronouncements.